Clinical development success rates for investigational drugs

被引：1670

作者：

Hay, Michael ^{[1
]}

Thomas, David W. ^{[2
]}

Craighead, John L. ^{[3
]}

Economides, Celia ^{[2
]}

Rosenthal, Jesse ^{[1
]}

机构：

[1] Sagient Res Syst, BioMedTracker, San Diego, CA 92122 USA

[2] BIO, Washington, DC USA

[3] Biotech Strategy & Analyt, Rockville, MD USA

来源：

NATURE BIOTECHNOLOGY | 2014年 / 32卷 / 01期

关键词：

PRODUCTIVITY; TRENDS; SCALE; RISKS; SCOPE;

D O I：

10.1038/nbt.2786

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates.

引用

页码：40 / 51

页数：12

共 20 条

[11]

Edelman M.J., 2010, 2010 AM SOC CLIN ONC

[12]

EvaluatePharma, 2012, WORLD PREV 2018 EMBR

[13] Scale, scope, and spillovers: The determinants of research productivity in drug discovery [J].

Henderson, R ;

Cockburn, I .

RAND JOURNAL OF ECONOMICS, 1996, 27 (01) :32-59

[14] Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009 [J].

Kaitin, K. I. ;

DiMasi, J. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) :183-188

[15] Can the pharmaceutical industry reduce attrition rates? [J].

Kola, I ;

Landis, J .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715

[16]

Lloyd I., 2011, PHARM R D ANN REV 20

[17] 2012 FDA drug approvals [J].

Mullard, Asher .

NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (02) :87-90

[18]

Pharmaceutical Research and Manufacturers of America, 2011, PHARM RES MAN AM ANN

[19] SUCCESS RATES IN THE UNITED-STATES DRUG DEVELOPMENT SYSTEM [J].

SHECK, L ;

COX, C ;

DAVIS, HT ;

TRIMBLE, AG ;

WARDELL, WM ;

HANSEN, R .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (05) :574-583

[20]

Tucker S.A., 1988, OUTCOME RES NEW MOL

← 1 2 →